

# Increased Mortality Risks of Pre-Diabetes (Impaired Fasting Glucose) in Taiwan

CHI PANG WEN, MD, DRPH<sup>1</sup>  
TING YUAN DAVID CHENG, MS<sup>2</sup>  
SHAN POU TSAI, PHD<sup>3</sup>

HUI LING HSU, MS<sup>1</sup>  
SHU LI WANG, PHD<sup>4</sup>

**OBJECTIVE** — The objective of this article was to assess mortality risks at different levels of fasting blood glucose (FBG) in Taiwan, with particular attention to those pre-diabetic subjects with impaired fasting glucose (IFG).

**RESEARCH DESIGN AND METHODS** — Governmental employees and schoolteachers were followed up for an average of 11 years. With the use of Cox regression analyses, mortality risks were calculated for 36,386 subjects, aged 40–69.

**RESULTS** — FBG  $\geq 110$  mg/dl was associated with increased mortality risks for all causes, cardiovascular diseases (CVD), and diabetes. IFG, when defined as 110–125 mg/dl, was associated with a significant increase for CVD and/or diabetes mortality. These mortality risks remained elevated when known CVD risk factors were adjusted for. The IFG group shared risk factor characteristics more with the FBG  $\geq 126$  mg/dl group than with the FBG  $< 110$  mg/dl group. When IFG was defined as 100–125 mg/dl, the number of subjects quadrupled, but mortality risks diminished substantially because of the inclusion of 100–109 mg/dl group. The lowest FBG group, 50–75 mg/dl, had a significant 2-fold risk from all causes.

**CONCLUSIONS** — There was an overall J-shaped relationship between all-cause mortality and FBG. IFG, when defined as 110–125 mg/dl, is an independent risk factor and should be aggressively treated as a disease because its subsequent mortality risks for CVD and diabetes were significantly increased. The newly defined IFG at 100–125 mg/dl did not have the predictive power for later increases in CVD or diabetes mortality.

*Diabetes Care* 28:2756–2761, 2005

Pre-diabetes, defined as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), has received increasing attention for its propensity to become diabetes and for the potential it presents for prevention (1–4). The definition of IFG, fasting blood glucose (FBG) at 110–125 mg/dl, was lowered to FBG 100–125 mg/dl in 2003 (5). Such a modification provoked controversy and was challenged as to its appropriateness (6–10). It reportedly would more than double the number of those

with pre-diabetes in the U.S. (6,11) or in Singapore (10). The basis for such lowering was not made immediately clear (5), but it seems to have come more from theoretical extrapolations from a few studies than from long-term outcome studies. For the purpose of predicting diabetes from pre-diabetes, the lowering of the IFG cut point was an attempt to reduce false-negative results and to increase true-positive results to the maximal extent. However, in so doing, a large number of false-positive results are created. Al-

though the benefits of early intervention have been assumed, whether it is still cost effective to intervene in a much larger population with pre-diabetes, one that more than doubles the original number of subjects with IFG, remains unsettled (6,8). Nevertheless, the recent change reflected the trend to lower the cut point for either diabetes or pre-diabetes by the American Diabetes Association (ADA) and the World Health Organization (WHO) (1,4), with the expectation that progression of pre-diabetes into diabetes or the development of cardiovascular diseases (CVD) can be prevented through earlier awareness and intervention (3, 12,13).

IFG, or pre-diabetes, is “not considered as a clinical entity in its own right, but rather a risk factor for future diabetes” (14). The reason is that, although IFG is associated with elevated mortality risks (2,15–21), these risks could attenuate or lose statistical significance when associated risk factors were adjusted. Because only a few studies assessed the long-term risks of IFG and were based mainly on Caucasian populations with largely inconclusive results (21–29), we evaluated this subject from an on-going large cohort study in Taiwan by calculating the mortality risks at different levels of FBG. Clarifying the predictive value of IFG will have important policy implications and will be useful for clinician’s management.

## RESEARCH DESIGN AND METHODS

Details of this cohort and its limitation have been reported elsewhere (30,31). The cohort studied in this article (36,386 subjects) was selected from a pool of more than 76,000 individuals, aged  $\geq 40$ , who went through an employer-sponsored medical examination program between 1989 and 1992. The subjects were mainly white-collar civil servants and teachers, with  $>75\%$  college graduates. In the course of medical check-ups, a medical history detailing, among other facts, the presence of physician-diagnosed diabetes or associated medication was recorded. In addition, a health risk appraisal questionnaire, eliciting lifestyle and health risk factors, was administered to each subject. Anthropometric and blood pressure measurements, collection of

From the <sup>1</sup>Division of Health Policy Research, National Health Research Institutes, Taiwan, Republic of China; the <sup>2</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; the <sup>3</sup>University of Texas, Health Science Center at Houston, Houston, Texas; and the <sup>4</sup>Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Taiwan, Republic of China.

Address correspondence and reprint requests to Chi Pang Wen, 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC. E-mail: cwengood@nhri.org.tw.

Received for publication 13 March 2005 and accepted in revised form 22 July 2005.

**Abbreviations:** ADA, American Diabetes Association; CVD, cardiovascular disease; DBP, diastolic blood pressure; DECODE, Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe; FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; SBP, systolic blood pressure; WHO, World Health Organization.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Comparison of risk factors among male and female subjects classified by FBG at time of recruitment

	FBG				Known diabetes	Total
	<100 mg/dl (5.6 mmol/l)	100–109 mg/dl (5.6–6.1 mmol/l)	110–125 mg/dl (6.1–6.9 mmol/l) (IFG)	≥126 mg/dl (>7.0 mmol/l) (screened diabetes)		
<b>Men</b>						
n (%)	14,772 (62.2)	5,703 (24.0)	1,857 (7.8)	816 (3.4)	607 (2.6)	23,755 (100)
Person-years observed	163,434	62,395	20,297	8,760	6,400	261,286
Age (years)	51.7 ± 0.07†	52.6 ± 0.11†	54.2 ± 0.18	55.9 ± 0.27†	58.0 ± 0.30†	52.4 ± 0.05
Fasting glucose						
mg/dl	91.4 ± 0.05	103.5 ± 0.04	115.1 ± 0.10	161.3 ± 1.56	164.5 ± 2.37	100.4 ± 0.14
mmol/l	5.1 ± 0.002	5.8 ± 0.002	6.4 ± 0.01	9.0 ± 0.09	9.1 ± 0.13	5.6 ± 0.01
SBP (mmHg)	117.3 ± 0.13†	121.8 ± 0.23†	126.1 ± 0.41	128.4 ± 0.64†	126.2 ± 0.73	119.7 ± 0.11
DBP (mmHg)	76.4 ± 0.08†	79.0 ± 0.14†	80.9 ± 0.25	81.0 ± 0.37	78.1 ± 0.43†	77.6 ± 0.07
Total serum cholesterol (mg/dl)	194.2 ± 0.28†	199.3 ± 0.46*	202.9 ± 0.81	204.4 ± 1.40	194.9 ± 1.37†	196.5 ± 0.22
BMI (kg/m <sup>2</sup> )	23.6 ± 0.02†	24.4 ± 0.04*	25.0 ± 0.06	25.3 ± 0.10*	24.7 ± 0.12*	24.0 ± 0.02
Smoking prevalence (%)						
Current smoker	30.1	26.7	27.1	32.8	31.8	29.2
Ex-smoker	14.2	17.0	19.0	20.3	22.4	15.7
<b>Women</b>						
n (%)	9,805 (77.6)	2,032 (16.1)	499 (4.0)	161 (1.3)	134 (1.1)	12,631 (100)
Person-years observed	108,889	22,264	5,449	1,780	1,481	139,864
Age (years)	47.3 ± 0.06†	49.5 ± 0.16†	51.4 ± 0.32	52.8 ± 0.59*	54.8 ± 0.61†	47.9 ± 0.06
Fasting glucose						
mg/dl	90.3 ± 0.06	103.3 ± 0.06	114.8 ± 0.19	160.9 ± 3.31	170.8 ± 5.0	95.1 ± 0.14
mmol/l	5.0 ± 0.003	5.7 ± 0.003	6.4 ± 0.01	8.9 ± 0.18	9.49 ± 0.28	5.3 ± 0.01
SBP (mmHg)	111.8 ± 0.16†	117.5 ± 0.39†	123.2 ± 0.89	129.7 ± 1.97†	125.7 ± 1.73	113.6 ± 0.15
DBP (mmHg)	72.1 ± 0.10†	75.1 ± 0.23†	77.4 ± 0.49	79.9 ± 1.08*	76.8 ± 1.00	73.0 ± 0.09
Total serum cholesterol (mg/dl)	193.0 ± 0.34†	201.6 ± 0.80†	211.1 ± 1.63	214.2 ± 3.27	210.8 ± 3.54	195.5 ± 0.31
BMI (kg/m <sup>2</sup> )	22.3 ± 0.03†	23.2 ± 0.06†	24.3 ± 0.15	24.6 ± 0.24	24.4 ± 0.29	22.6 ± 0.03
Smoking prevalence (%)						
Current smoker	1.3	1.1	1.2	1.2	2.2	1.3
Ex-smoker	0.4	0.7	0.8	0.6	0.8	0.5

Data are means ± SE unless otherwise indicated. Differences from IFG, \**P* < 0.05, †*P* < 0.01.

blood, and laboratory analyses were performed, in addition to hands-on physical examinations by physicians.

### Blood analysis

All subjects visited one centrally located clinic in Taipei City in the morning after overnight fasting. Venous blood specimens collected were centrifuged shortly afterward, within 30 min, for analysis. Specimens were then processed with a Hitachi 730-20 AutoAnalyzer using the glucose oxidase method for FBG analysis (Wako, Osaka, Japan). For description of characteristics, the cohort was divided into five groups, those with FBG <100 mg/dl, 100–109 mg/dl, 110–125 mg/dl (IFG), ≥126 mg/dl (screened diabetes), and subjects with known diabetes.

### Outcome follow-up

A nationwide mortality computer file has been maintained by the government since 1971. In this study, a search was conducted on data from 1990 to 2001 from this Taiwan mortality file. We limited our mortality analysis to men (*n* = 23,755) because of the small number of female deaths. By the end of 2001, 1,060 male deaths were identified and coded, using the WHO ICD-9 (32).

### Statistical analysis

Relative risks were calculated by comparing the age-adjusted mortality rates of different levels of FBG with the reference group, FBG between 90 and 109 mg/dl. In addition, another reference group, defined as FPG 90–99 mg/dl, was used to assess differences in relative risks from the recently revised IFG definition (5). A Cox

proportionate hazard model was used to make adjustments on CVD risk factors, i.e., systolic blood pressure (SBP) (≥140 or <140 mmHg), diastolic blood pressure (DBP) (≥90 or <90 mmHg), smoking (never, ex-smoker, or current smoker), total serum cholesterol (≥240 or <240 mg/dl), and BMI (≥24 or <24 kg/m<sup>2</sup>). The cut points selected for cholesterol at 240 mg/dl (33) and BMI at 24 kg/m<sup>2</sup> (34–36) in risk adjustment were based on data from the literature.

**RESULTS**— IFG 110–125 mg/dl includes 7.8% of men and 4.0% of women (Table 1), and the group is ~3 times the size of the group with “known diabetes” (2.6% of men and 1.1% of women) and twice the size of the additional group with “screened diabetes” (3.4% of men and 1.3% of women). The addition of those

Table 2—Relative mortality risks for different levels of FBG (for IFG at 110–125 mg/dl, using 90–109 and 90–99 mg/dl as reference)

Glucose, mg/dl (mmol/l)	n	All-causes			CVD			Diabetes			CVD and diabetes		
		Deaths	RR*	RR†	Deaths	RR*	RR†	Deaths	RR*	RR†	Deaths	RR*	RR†
90–109 mg/dl as reference													
Total	23,755	1,060			256			53			309		
50–75 (2.8–4.1)	129	12	2.1‡	2.0‡	2	1.5	1.4	0	NA	NA	2	1.4	1.4
76–89 (4.2–4.9)	4,706	205	1.1	1.2	37	0.8	0.9	2	1.3	1.3	39	0.9	0.9
90–109 (5.0–6.0)	15,640	580	1.0	1.0	142	1.0	1.0	5	1.0	1.0	147	1.0	1.0
110–125 (6.1–6.9) (IFG)	1,857	79	1.0	0.9	29	1.5‡	1.3	3	4.4‡	4.3‡	32	1.6‡	1.4
126–139 (7.0–7.7)	371	26	1.4	1.3	4	0.9	0.7	4	24.0‡	22.6‡	8	1.7	1.4
140–179 (7.8–9.9)	270	25	1.8‡	1.6‡	11	3.1‡	2.6‡	3	22.4‡	21.2‡	14	3.8‡	3.2‡
180+ (10.0+)	175	27	3.7‡	3.6‡	8	4.4‡	3.9‡	8	122.2‡	125.6‡	16	8.5‡	7.6‡
Known diabetic subjects	607	106	3.3‡	3.1‡	23	2.9‡	2.6‡	28	99.4‡	95.2‡	51	6.2‡	5.6‡
90–99 mg/dl as reference													
Total	23,755	1,060	—	—	254	—	—	53	—	—	307	—	—
50–75 (2.8–4.1)	129	12	2.1‡	1.9‡	2	1.5	1.4	0	—	—	2	1.4	1.4
76–89 (4.2–4.9)	4,706	205	1.1	1.1	36	0.8	0.9	2	2.0	2.0	38	0.9	1.9
90–99 (5.0–5.5)	9,937	369	1.0	1.0	86	1.0	1.0	2	1.0	1.0	88	1.0	1.0
100–125 (5.6–6.9) (IFG)	7,560	290	1.0	0.9	84	1.2	1.0	6	3.6	3.6	90	1.2	1.1
100–109 (5.6–6.1)	5,703	211	0.9	0.9	55	1.0	1.0	3	2.4	2.5	58	1.1	1.0
110–125 (6.1–6.9)	1,857	79	1.0	0.9	29	1.5‡	1.3	3	6.8‡	7.0‡	32	1.7‡	1.4
126–139 (7.0–7.7)	371	26	1.4	1.2	4	0.9	0.7	4	38.7‡	38.0‡	8	1.8	1.4
140–179 (7.8–9.9)	270	25	1.8‡	1.6‡	11	3.2‡	2.5‡	3	37.9‡	37.7‡	14	4.0‡	3.3‡
180+ (10.0+)	175	27	3.7‡	3.5‡	8	4.5‡	3.8‡	8	197.5‡	209.5‡	16	8.9‡	7.8‡
Known diabetic subjects	607	106	3.1‡	2.9‡	23	2.7‡	2.4‡	28	146.4‡	141.5‡	51	6.0‡	5.4‡

Data are *n* unless otherwise indicated. \*RR adjusted for age only. †RR adjusted for age, SBP ( $\geq 140$  mmHg), smoking (never, ex-smoker, and current smoker), total serum cholesterol ( $\geq 240$  mg/dl), and BMI ( $\geq 24$  kg/m<sup>2</sup>). ‡*P* < 0.05. Reference group was based on 90–109 mg/dl for all levels. CVD, ICD-9: 401–448; diabetes, ICD-9: 250.

with FBG 100–109 mg/dl (24.0% of men and 16.1% of women) as a newly defined group with IFG would at least quadruple the number of those with IFG, making the new group with IFG to be 31.8% in men and 20.1% in women. The IFG group showed significantly higher SBP, DBP, cholesterol level, and BMI than those with FBG at <100 mg/dl or 100–109 mg/dl, in both men and women. The means for SBP, DBP, cholesterol level, or BMI for men in the IFG group was closer to that for those with screened diabetes than for those with FBG <109 mg/dl. A similar trend was generally seen for women.

With the use of those with FBG at 90–109 mg/dl as the group to compare with, those with IFG at 50–75, 140–179, and  $\geq 180$  mg/dl and those with known diabetes showed significantly increased risks for all-cause mortality (Table 2). For those with the three FBG levels  $\geq 126$  mg/dl, i.e., 126–139, 140–179, and  $\geq 180$ , mortality risks for CVD, diabetes, or CVD and diabetes combined, generally increased with increasing levels of blood glucose. A similar pattern of mortality increases was seen for the known diabetes group, with the magnitude of the increase similar to that for the group at  $\geq 180$  mg/


dl. The IFG group, defined as 110–125 mg/dl, had significantly increased mortality risks for CVD, diabetes, and CVD and diabetes. Upon adjustments for CVD risk factors, all increased relative risks (RRs) for IFG remained elevated. Specifically, the adjusted RR for CVD and diabetes at 1.4 was borderline significant, with *P* = 0.08. With those with FBG 90–99 mg/dl being used as the comparison group in Table 2, the 100–125 mg/dl group, the group recently classified as having IFG by ADA criteria (5), failed to show significant increases in either all-cause or CVD mortality. When this group was split into two, 100–109 mg/dl and 110–125 mg/dl, and examined separately, the latter group, but not the former, had a significantly increased risk for CVD, diabetes, or both.

The relationships between FPG and mortality risks for all causes are graphically presented in Fig. 1. The J-shaped curve reflects increases at both ends of the FBG spectrum and remained similar with the inclusion of known diabetes.

Table 3 shows relative risks at different FBG levels, with those having FBG above each specified level being compared with those having FBG below that level. Four levels were selected: 100, 110,

126, and 140 mg/dl. The all-cause mortality risks increased by 30, 90, and 130% for those with FBG level  $\geq 110$ , 126, or 140 mg/dl, when compared with those with FBG below that level, respectively. In contrast, the risks among those with FBG above the cut point at 100 mg/dl failed to show significant increases for all-cause or for CVD mortality, although increases were found for diabetes or CVD and diabetes.

**CONCLUSIONS**— This study found an overall J-shaped relationship between all-cause mortality and levels of FBG in an Asian population, with significant increases in mortality, starting at  $\geq 110$  mg/dl as well as  $\leq 75$  mg/dl. The higher the FBG  $\geq 110$  mg/dl, the more the risks increased. This increased risks at both ends of the FBG spectrum to form a similar J-shaped relationship has been observed in several Caucasian populations (37–39). In the Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) study, an RR = 1.2 for all-cause mortality was seen among those with FBG  $\leq 81$  mg/dl (37). Similarly, in the San Antonio Heart Study, those with FBG <70 mg/dl had a 3.3-fold higher risk of CVD mortality compared



**Figure 1**—Relative risks for all-cause mortality by levels of fasting blood glucose on subjects with no history of diabetes. Vertical bars represent 95% CI. \* $P < 0.05$  vs. those at 90–109 mg/dl. \*\*Relative risks adjusted for age, systolic blood pressure ( $\geq 140$  mmHg), smoking (never, ex-smoker, and current smoker), total serum cholesterol ( $\geq 240$  mg/dl), and BMI ( $\geq 24$  kg/m<sup>2</sup>).

with those with FBG 80–109 mg/dl (39). With a cutoff at 75 mg/dl, our data substantiated an increase for all-cause mortality (RR = 2.0) but not for CVD mortality. A recent report from 17 pooled studies in the Asian Pacific region (19), showing a dose-response benefit of reducing CVD burden when FBG was lowered to a level of  $\leq 90$  mg/dl, was in line with the findings from this study. A note of caution should be added for those expecting the risk to continue to be reduced as FBG becomes lower and lower. In our study, FBG  $< 75$  mg/dl was actually associated with a higher, not lower, risk for all-cause mortality. If validated in other populations and if found not to reflect the presence of other pathologic conditions, this finding of a J-shaped relationship with increased mortality risk at FBG  $< 75$  mg/dl may have important implications in the clinical management of glucose control.

This study confirms the tendency of the IFG group, defined as 110–125 mg/dl, to have a severe risk of CVD. The characteristics of subjects with IFG have contributed to the widely held concept that the reason IFG was associated with increased CVD mortality was because subjects with IFG had additional or more severe risk factors, and, therefore, IFG per se is not an independent risk (2,15,17,22–29,40,41). Nevertheless, this study showed for the first time that

the increased risks of IFG remained significantly elevated, even after CVD risk factors were adjusted. In other words, IFG is capable of predicting future mortality independently, and identifying someone with IFG is not an incidental or innocent finding. Contrary to the consensus statement previously reported (2,3), IFG is more than just a risk marker for future diabetes. First, anyone with FBG  $\geq 110$  mg/dl (Table 3) was shown to have substantially increased risks for all-cause and CVD mortality, with excess risks as much as 140% for CVD and diabetes. Second, IFG per se caused higher mortality for CVD and/or diabetes (Table 2). Obviously, these individuals were indeed vulnerable, not only because they tended to be associated with additional CVD risk profiles, but also because they had an ad-

ditional unique, independent risk in having FBG at 110–125 mg/dl. Thus, a simple blood test to uncover IFG can predict substantial mortality risks for CVD and diabetes among nondiabetic individuals, hitherto vaguely recognized (2,15,17,22–29). The failure of previous studies to identify such risks may have come more from the inadequate sample size of study cohorts than from a true absence of risks (15,17,18,23–27).

The excess risks of IFG were demonstrated within 11 years, a relatively short time, implying that an urgency exists for preventive actions in those with IFG. In the meantime, a mechanism to identify those in the high-risk IFG group and to retard the progression of IFG should be pursued (2,14). The recent designation of smoking as “a chronic addictive disease” (42) has facilitated the implementation of smoking cessation programs in the clinical setting. Similarly, making IFG a treatable condition or recognizing it as a disease would legitimize early intervention. It should be emphasized that much of the intervention for IFG is to institute sustainable lifestyle changes (43,44).

Even though the results in this study came from a cohort with higher education, the increased risks of IFG seen in this study can be a reasonable estimate for those in the general population because risk estimation was based on internal comparison with persons with similar socioeconomic status. Some practices in this study resulted in consistent quality: collecting a history and examining subjects under one protocol from one single clinic and analyzing blood samples in the same laboratory with the same machine by the same trained staffs using the same methodology. The independently increased risk of IFG found in this study is in contrast to results of published reports of IFG based mostly on pooled studies (19,23,26,28,37,45,46), which are affected by inconsistent quality or wide variations, including

**Table 3**—RRs comparing FBG\* levels for subsequent mortality in male subjects

Glucose [mg/dl (mmol/l)]	n (deaths)	All-cause	CVD	Diabetes	CVD and diabetes
$\geq 100$ (5.6+)	8,376 (368)	1.0 (0.8–1.1)	1.2 (0.9–1.5)	7.8 (2.6–22.9)	1.4 (1.1–1.7)
$\geq 110$ (6.1+)	2,673 (157)	1.3 (1.1–1.5)	1.8 (1.4–2.5)	15.7 (6.5–37.6)	2.4 (1.8–3.1)
$\geq 126$ (7.0+)	816 (78)	1.9 (1.5–2.4)	2.3 (1.5–3.5)	29.5 (13.1–66.5)	3.6 (2.5–5.1)
$\geq 140$ (7.8+)	445 (52)	2.3 (1.8–3.1)	3.5 (2.2–5.6)	29.0 (12.9–65.2)	5.2 (3.5–7.6)

Data are RRs adjusted for age, SBP ( $\geq 140$  mmHg), smoking (never, ex-smoker, and current smoker), total serum cholesterol level ( $\geq 240$  mg/dl), and BMI ( $\geq 24$  kg/m<sup>2</sup>). \*Each level of FBG indicates a comparison of mortality risks of those at or above the level with those below that level. CVD, ICD-9: 401–448; diabetes, ICD-9: 250.

differences in the age or morbidity distribution of subcohorts.

The cut point for our reference group, FBG 90–109 mg/dl, was selected because of its lowest risk in our study subjects. An identical cut point was chosen by de Vegt et al. (15) and by the Asia Pacific Cohort Studies Collaboration (19). This is because, given the J-shaped relationship of FBG with mortality risk, lower levels of glucose carried some adverse risks in this and other studies. In fact, similar observations were made by the DECODE group, which reported the lowest mortality risks in subjects with FPG at 4.5–5.0 mmol/l (80–90 mg/dl) for all-cause mortality or 5.0–5.5 mmol/l (90–100 mg/dl) for CVD mortality (37) and by Balkau et al. (38), who also concluded that the lowest mortality rate was seen among subjects in the group with FBG 5.25–5.75 mmol/l (95–104 mg/dl). All of these data indicate that the inclusion of any group with FBG <90 mg/dl may not be the best reference group.

Although IFG was reportedly less sensitive in its predictive value for diabetes or CVD than was IGT (2,23,24,26), FBG has been universally recognized as a preferred mode of diabetes screening, with the test being easier to perform, more convenient and acceptable to patients, more reproducible, and, most importantly, less expensive (47). These advantages are further magnified in Asian populations, particularly because the cost of screening has always been an overriding concern.

Most studies examining the mortality outcome of high blood glucose have focused mainly on deaths from CVD and not from diabetes (2,21,23–26,29,41), but in our study, mortality from diabetes as an additional end point was included. First, as shown in this cohort, a strong association between various glucose levels and subsequent deaths coded to diabetes supports their causal relationships: RR as large as 4.3 for 110–125 mg/dl, 22.6 for 126–139 mg/dl, 21.2 for 140–179 mg/dl, and 125.6 for  $\geq 180$  mg/dl (Table 2). Second, more deaths were coded to diabetes in Taiwan than elsewhere: Diabetes ranked as the fourth leading cause of deaths in Taiwan, and constituted 7.7% of all deaths (48). This proportion was far larger than its counterparts in the U.S. of 3.0% (49,50) or in Japan of 1.3% (51), even though the prevalence of diabetes in Taiwan was not much higher (52). The age-adjusted mortality rates, 57.7 and 74.0, for men and for women in Taiwan (48) were more than

twice as large than those in the U.S. (28.6 and 23.0) (49,50) or 6–10 times larger than those in Japan (9.1 and 5.9 per 100,000) (51), respectively. This gap between Taiwan and the U.S. or Japan has been widening because the mortality rate for diabetes in Taiwan has been rapidly increasing (53). This higher proportion of deaths from diabetes has been shown not to be due to a coding artifact (53,54) or to a true increase in the prevalence of diabetes (52) but is more reflective of the preference by physicians in assigning diabetes as the underlying cause of death when filling out death certificates. Based on these considerations, we felt these deaths coded to diabetes should be considered along with CVD deaths in accounting for all diabetes-related deaths.

This study shows that the new ADA criteria for IFG, defining IFG as 100–125 mg/dl, instead of as 110–125 mg/dl, have substantially weakened the predictive power of mortality outcome. By including the 100–109 mg/dl group, the new IFG criteria quadrupled the number of subjects in this cohort, from 7.8% to 24.0%. However, this inclusion was found to produce almost no increase in mortality risks. As the new population with IFG becomes statistically not different from those with IFG below this level, mainly because of the inclusion of this 100–109 mg/dl group, the new definition of IFG cannot be justified from the mortality perspective.

In summary, there was an overall J-shaped relationship between all-cause mortality and FBG. IFG, traditionally defined as 110–125 mg/dl, is an independent risk factor and should be aggressively treated as a disease, because it produced a significant increase in combined CVD and diabetes mortality risks in this Asian population. The increase in risk and the predictive value of IFG disappeared when IFG was defined as 100–125 mg/dl, making the necessity of the new IFG definition questionable.

## References

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183–1197, 1997
2. Unwin N, Shaw J, Zimmet P, Alberti KGMM: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet Med* 19:708–723, 2002
3. The Expert Committee on the Diagnosis

and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 26 (Suppl. 1):S5–S20, 2003

4. World Health Organization: Part 1: diagnosis and classification of diabetes mellitus. In *Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications*. Geneva, World Health Org., 1999
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26:3160–3167, 2003
6. Davidson MB, Landsman PB, Alexander CM: Lowering the criterion for impaired fasting glucose will not provide clinical benefit. *Diabetes Care* 26:3329–3330, 2003
7. Genuth S: Lowering the criterion for impaired fasting glucose is in order. *Diabetes Care* 26:3331–3312, 2003
8. Schriger DL, Lorber B: Lowering the cut point for impaired fasting glucose: Where is the evidence? Where is the logic? *Diabetes Care* 27:592–595, 2004
9. Engelgau MM: Diabetes diagnostic criteria and impaired glycaemic states: evolving evidence base. *Clin Diabetes* 22:69–70, 2004
10. Tai ES, Goh SY, Lee JJM, Wong MS, Heng D, Hughes K, Chew SK, Cutter J, Chew W, Gu K, Chia KS, Tan CE: Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. *Diabetes Care* 27:1728–1734, 2004
11. U.S. Department of Health and Human Services: News release: revised definition means millions more have pre-diabetes [article online], 29 April 2004. Available from <http://www.os.dhhs.gov/news/press/2004.html#Apr>. Accessed 10 January 2005
12. Gerstein HC: Preventive medicine in a diabetes clinic: an opportunity to make a difference. *Lancet* 353:606–608, 1999
13. Gæde P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet* 353:617–622, 1999
14. American Diabetes Association: Diagnosis and classification of diabetes mellitus. *Diabetes Care* 28:37–42, 2005
15. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 42:926–931, 1999
16. Simons LA, Friedlander Y, McCallum J, Simons J: Fasting plasma glucose in nondiabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. *Aust N Z J Med* 30:41–47, 2000

17. Rajala U, Koskela P, Keinanen-Kiukkaaniemi S: Hyperglycemia as a risk factor of mortality in a middle-aged Finnish population. *J Clin Epidemiol* 54:470–474, 2001
18. Ma S, Cutter J, Tan CE, Chew SK, Tai ES: Associations of diabetes mellitus and ethnicity with mortality in a multiethnic Asian population: data from 1992 Singapore National Health Survey. *Am J Epidemiol* 158:543–552, 2003
19. Asia Pacific Cohort Studies Collaboration: Blood glucose and risk of cardiovascular disease in the Asia Pacific region. *Diabetes Care* 27:2836–2842, 2004
20. Hu G, the DECODE Study Group: Gender difference in all-cause and cardiovascular mortality related to hyperglycemia and newly-diagnosed diabetes. *Diabetologia* 46:608–617, 2003
21. Charles MA, Balkau B, Vauzelle-Kervroedan F, Thibault N, Eschwege E: Revision of diagnostic criteria for diabetes. *Lancet* 14: 1657–1658, 1996
22. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. *Diabetes Care* 21:360–367, 1998
23. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med* 161:397–405, 2001
24. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. *Diabetes Care* 22:920–924, 1999
25. Saydah S, Miret M, Sung J, Varas C, Gause D, Brancati F: Postchallenge hyperglycemia and mortality in national sample of U.S. adults. *Diabetes Care* 24:1397–1402, 2001
26. Nakagami T, DECODA Study Group: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. *Diabetologia* 47:385–394, 2004
27. Heldgaard PE, Olivarius NF, Hindsberger C, Henriksen JE: Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease. *Diabet Med* 21:363–370, 2004
28. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and mortality comparison of WHO and American Diabetes Association diagnostic criteria. *Lancet* 354:617–621, 1999
29. Alexander CM, Landsman PB, Teutsch SM: Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. *Am J Cardiol* 86:897–902, 2000
30. Wen CP, Tsai SP, Chen CJ, Cheng TY: The mortality risks of smokers in Taiwan. Part I: cause-specific mortality. *Prev Med* 39: 528–535, 2004
31. Wen CP, Cheng TY, Lin CL, Wu HN, Levy DT, Chen LK, Hsu CC, Eriksen MP, Yang HJ: The health benefits of smoking cessation for adult smokers and for pregnant women in Taiwan. *Tob Control* 2005;14 (Suppl. 1):i56–i61
32. World Health Organization: *International Classification of Disease*. Rev. 9. Geneva, World Health Org., 1975
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 285: 2486–2497, 2001
34. WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 363:157–163, 2004
35. Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, Lin RS, Shau WY, Huang KC: Optimal cut-off values for obesity: using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. *Int J Obes Relat Metab Disord* 26:1232–1238, 2002
36. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in China: Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci* 15:83–96, 2002
37. The DECODE Study Group, the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular disease? *Diabetes Care* 26:688–696, 2003
38. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? *Diabetes Care* 22:696–699, 1999
39. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN: Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. *Circulation* 101:2047–2052, 2000
40. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM: Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. *Diabetes Care* 53:2095–2100, 2004
41. Henry P, Thomas F, Benetos A, Guize L: Impaired fasting glucose, blood pressure and cardiovascular disease mortality. *Hypertension* 40:458–463, 2002
42. U.S. Department of Health and Human Services, Public Health Service: *Clinical Practice Guideline: Treating Tobacco Use and Dependence*. Silver Spring, MD, Publications Clearinghouse, 2000, p. 9–10
43. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393–403, 2002
44. Narayan KMV, Benjamin SM, Engelgau MM: Targeting people with pre-diabetes: lifestyle interventions should also be aimed at people with pre-diabetes. *BMJ* 325:403–404, 2002
45. Asia Pacific Cohort Studies Collaboration: The effect of diabetes on the risk of major cardiovascular disease and death in the Asia-Pacific region. *Diabetes Care* 26:360–366, 2003
46. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care* 22:233–240, 1999
47. American Diabetes Association: Screening for type 2 diabetes. *Diabetes Care* 27(Suppl. 1):S11–S14, 2004
48. Taiwan Department of Health: *Health and Vital Statistics*. Vol. 2. Taiwan, Vital Statistics, 2003
49. Kochanek K, Murphy S, Anderson RN, Scott C: Deaths: final data for 2002. *Natl Vital Stat Rep* 53, No. 5, 2004
50. U.S. Department of Health and Human Services, Public Health Service: *Health and vital statistics*. 1. General health statistics. Hyattsville, MD, Centers for Disease Control and Prevention, National Center for Health Statistics, 2000
51. Japan Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labor and Welfare: *Vital Statistics of Japan*. Vols. 1 and 3. Tokyo, Japan Health and Welfare Statistics Association, 2001
52. Pan WH, Yeh WT, Chang HY, Hwu CM, Ho LT: Prevalence and awareness of diabetes and mean fasting glucose by age, sex, and region: results from the Nutrition and Health Survey in Taiwan, 1993–1996. *Diabet Med* 20:182–185, 2003
53. Lu TH: Is high diabetes mortality in Taiwan due to coding artifact? Implications for international comparisons (Letter). *Diabetes Res Clin Pract* 60:75–76, 2003
54. Lu TH, Lee MC, Chou MC: Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. *Int J Epidemiol* 29:336–343, 2000